The influence of obesity on survival in early, high-risk breast cancer: Results from the randomized SUCCESS A trial

Breast Cancer Research

Volumn 17, Issue 1, 2015, Pages

  Widschwendter, Peter ^a   Friedl, Thomas WP ^a   Schwentner, Lukas ^a   DeGregorio, Nikolaus ^a   Jaeger, Bernadette ^a   Schramm, Amelie ^a   Bekes, Inga ^a   Deniz, Miriam ^a   Lato, Krisztian ^a   Weissenbacher, Tobias ^b   Kost, Bernd ^b   Andergassen, Ulrich ^b   Jueckstock, Julia ^b   Neugebauer, Julia ^b   Trapp, Elisabeth ^b   Fasching, Peter A ^c   Beckmann, Matthias W ^c   Schneeweiss, Andreas ^d   Schrader, Ines ^e   Rack, Brigitte ^b   Janni, Wolfgang ^a   Scholz, Christoph ^a   more..

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e Gynecologic Oncological Office   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; TAMOXIFEN; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; DEOXYCYTIDINE; ERBB2 PROTEIN, HUMAN; TAXANE; TAXOID;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; BREAST CANCER; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG SUBSTITUTION; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MAJOR CLINICAL STUDY; NORMAL BODY WEIGHT; OBESITY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER; UNDERWEIGHT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; FEMALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BODY MASS INDEX; BRIDGED-RING COMPOUNDS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; OBESITY; OVERWEIGHT; PROGNOSIS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TAXOIDS; TRIPLE NEGATIVE BREAST NEOPLASMS; YOUNG ADULT;

EID: 84958890227     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-015-0639-3     Document Type: Article

References (18)

1. Haslam DW, James WPT. Obesity. Lancet. 2005;366:1197-209.
2. Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA. 2007;298:2028-37.
3. Chan DSM, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol. 2014;25:1901-14. doi: 10.1093/annonc/mdu042.
4. Berclaz G. Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol. 2004;15:875-84.
5. De Azambuja E, McCaskill-Stevens W, Francis P, Quinaux E, Crown JPA, Vicente M, et al. The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat. 2010;119:145-53.
6. Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA, et al. Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer. 2012;118:5937-46.
7. Pajares B, Pollán M, Martín M, Mackey JR, Lluch A, Gavila J, et al. Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis. Breast Cancer Res. 2013;15:R105.
8. Andergassen U, Kasprowicz NS, Hepp P, Schindlbeck C, Harbeck N, Kiechle M, et al. Participation in the SUCCESS A Trial improves intensity and quality of care for patients with primary breast cancer. Geburtshilfe Frauenheilkd. 2013;73:63-9.
9. Berrington De Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med. 2010;363:2211-9.
10. Lux MP, Maass N, Schütz F, Schwidde I, Fasching PA, Fehm T, et al. Breast cancer 2013 - Interpretation of new and known data. Geburtshilfe Frauenheilkd. 2013;73:584-98.
11. Perou CM, Borresen-Dale AL. Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol. 2011;3:1-17.
12. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123:627-35.
13. Scholz C, Andergassen U, Hepp P, Schindlbeck C, Friedl TWP, Harbeck N, et al. Obesity as an independent risk factor for decreased survival in node-positive high-risk breast cancer. Breast Cancer Res Treat. 2015;151:569-76.
14. Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the women's health initiative randomized clinical trials. JAMA Oncol. 2015;1:611-21.
15. Niraula S, Ocana A, Ennis M, Goodwin PJ. Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis. Breast Cancer Res Treat. 2012;134:769-81.
16. Fontanella C, Lederer B, Gade S, Vanoppen M, Blohmer JU, Costa SD, et al. Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials. Breast Cancer Res Treat. 2015;150:127-39.
17. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med. 2013;159:758-69.
18. Bhandari R, Kelley GA, Hartley TARI. Metabolic syndrome is associated with increased breast cancer risk: a systematic review with meta-analysis. Int J Breast Cancer. 2014;2014:189384. doi: 10.1155/2014/189384.